PMID- 26992070
OWN - NLM
STAT- MEDLINE
DCOM- 20170428
LR  - 20220129
IS  - 1615-9861 (Electronic)
IS  - 1615-9853 (Print)
IS  - 1615-9853 (Linking)
VI  - 16
IP  - 10
DP  - 2016 May
TI  - High-sensitivity HLA class I peptidome analysis enables a precise definition of 
      peptide motifs and the identification of peptides from cell lines and patients' 
      sera.
PG  - 1570-80
LID - 10.1002/pmic.201500445 [doi]
AB  - The characterization of peptides bound to human leukocyte antigen (HLA) class I 
      is of fundamental importance for understanding CD8+ T cell-driven immunological 
      processes and for the development of immunomodulatory therapeutic strategies. 
      However, until now, the mass spectrometric analysis of HLA-bound peptides has 
      typically required billions of cells, still resulting in relatively few 
      high-confidence peptide identifications. Capitalizing on the recent developments 
      in mass spectrometry and bioinformatics, we have implemented a methodology for 
      the efficient recovery of acid-eluted HLA peptides after purification with the 
      pan-reactive antibody W6/32 and have identified a total of 27 862 unique peptides 
      with high confidence (1% false discovery rate) from five human cancer cell lines. 
      More than 93% of the identified peptides were eight to 11 amino acids in length 
      and contained signatures that were in excellent agreement with published HLA 
      binding motifs. Furthermore, by purifying soluble HLA class I complexes (sHLA) 
      from sera of melanoma patients, up to 972 high-confidence peptides could be 
      identified, including melanoma-associated antigens already described in the 
      literature. Knowledge of the HLA class I peptidome should facilitate multiplex 
      tetramer technology-based characterization of T cells, and allow the development 
      of patient selection, stratification and immunomodulatory therapeutic strategies.
CI  - (c) 2016 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
FAU - Ritz, Danilo
AU  - Ritz D
AD  - Philochem AG, Otelfingen, Switzerland.
FAU - Gloger, Andreas
AU  - Gloger A
AD  - Institute of Pharmaceutical Sciences, ETH Zurich, Zurich, Switzerland.
FAU - Weide, Benjamin
AU  - Weide B
AD  - Department of Dermatology, Division of Dermatologic Oncology, 
      Eberhard-Karls-University, Tuebingen, Germany.
AD  - Department of Immunology, Eberhard-Karls-University, Tuebingen, Germany.
FAU - Garbe, Claus
AU  - Garbe C
AD  - Department of Dermatology, Division of Dermatologic Oncology, 
      Eberhard-Karls-University, Tuebingen, Germany.
FAU - Neri, Dario
AU  - Neri D
AD  - Institute of Pharmaceutical Sciences, ETH Zurich, Zurich, Switzerland.
FAU - Fugmann, Tim
AU  - Fugmann T
AD  - Philochem AG, Otelfingen, Switzerland.
LA  - eng
GR  - 670603/ERC_/European Research Council/International
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Germany
TA  - Proteomics
JT  - Proteomics
JID - 101092707
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Histocompatibility Antigens Class I)
RN  - 0 (Peptides)
SB  - IM
MH  - Amino Acid Motifs
MH  - Amino Acid Sequence
MH  - Antigens, Neoplasm/blood
MH  - Biomarkers, Tumor/*blood/isolation & purification
MH  - Case-Control Studies
MH  - Consensus Sequence
MH  - HEK293 Cells
MH  - HL-60 Cells
MH  - Histocompatibility Antigens Class I/*physiology
MH  - Humans
MH  - Melanoma/*blood
MH  - Peptides/*blood/isolation & purification
MH  - Protein Binding
MH  - Protein Interaction Domains and Motifs
MH  - Spondylitis, Ankylosing/blood
PMC - PMC5557336
MID - EMS70748
OTO - NOTNLM
OT  - Biomedicine
OT  - HLA class I
OT  - Immunopeptidomics
OT  - Melanoma
OT  - sHLA tumor-associated epitopes
COIS- Conflict of Interest Disclosure Dario Neri is co-founder, shareholder and member 
      of the board of Philogen.
EDAT- 2016/03/19 06:00
MHDA- 2017/04/30 06:00
PMCR- 2017/08/15
CRDT- 2016/03/19 06:00
PHST- 2015/11/12 00:00 [received]
PHST- 2016/02/09 00:00 [revised]
PHST- 2016/02/23 00:00 [accepted]
PHST- 2016/03/19 06:00 [entrez]
PHST- 2016/03/19 06:00 [pubmed]
PHST- 2017/04/30 06:00 [medline]
PHST- 2017/08/15 00:00 [pmc-release]
AID - 10.1002/pmic.201500445 [doi]
PST - ppublish
SO  - Proteomics. 2016 May;16(10):1570-80. doi: 10.1002/pmic.201500445.